NRX Pharmaceuticals

NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded on September 18, 2017 and is headquartered in Wilmington, DE.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

NRx Pharmaceuticals reports strong Q1 performance and growth opportunities

NRx Pharmaceuticals made strides in innovation, debt reduction, and financial stability in Q1 2024.
The company's focus on mental health treatments and addressing unmet medical needs shows market relevance.
Challenges include resolving short interest concerns and securing FDA approvals for key drugs.
Opportunities lie in out-licensing, revenue generation, and partnerships for growth and market expansion.

NRx Pharmaceuticals reports progress in financials and scientific breakthroughs

NRx Pharmaceuticals showcased financial and scientific progress, positioning itself for growth and market penetration.
Strategic initiatives like clinic roll-up and commercial targeting demonstrate a proactive approach to market challenges.
While facing transitions and competition, NRx Pharmaceuticals has opportunities for expansion and innovation in psychiatric treatments.
The company's focus on financial stability, product development, and market strategies reflects a comprehensive growth strategy.

NRx Pharmaceuticals reports improved financials and plans for growth

NRx Pharmaceuticals demonstrated improved financial performance and strategic planning in Q3 2024, with reduced losses and enhanced operational efficiency.
The company's focus on innovation, acquisitions, and precision psychiatry clinics highlights a commitment to growth and market leadership.
While facing challenges in revenue recognition and clinic valuations, NRx Pharmaceuticals has opportunities to drive revenue growth and expand its market presence.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

RADNOR, Pa. , June 6, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced that it has entered into definitive agreements for the purchase and sale of 9,670,002 shares of common stock at a purchase price of $0.65 per share of common stock in a registered direct offering.

NRx Pharmaceuticals Announces $6.28 Million Registered Direct Offering

RADNOR, Pa. and MORRISTOWN, N.J. and TAIPEI, Taiwan, June 05, 2023 (GLOBE NEWSWIRE) -- Lotus Pharmaceuticals (1795:TT; “Lotus”), a multinational pharmaceutical company, Alvogen, a privately owned U.S. based pharmaceuticals company, and NRx Pharmaceuticals Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals or NRx”), a clinical stage biopharmaceutical company, today announced a global collaboration agreement covering the development and commercialization of NRX-101 for suicidal treatment-resistant bipolar depression (S-TRBD) for global markets.

NRx Pharmaceuticals, Lotus Pharmaceuticals and Alvogen Inc. Announce Collaboration to Develop and Commercialize NRX-101

RADNOR, Pa. , June 2, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced it will host a corporate and strategic update conference call on Monday, June 5, 2023 at 8:30 a.m.

NRx Pharmaceuticals to Host Corporate and Strategic Update Conference Call on Monday, June 5, 2023

NRx Pharmaceuticals, Inc. (NRXP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About NRx Pharmaceuticals, Inc. (NRXP) Rating Upgrade to Buy

NEW YORK , May 26, 2023 /PRNewswire/ -- Jakubowitz Law announces that a merger investigation has commenced on behalf of shareholders of NRx Pharmaceuticals Inc.  (f/k/a Big Rock Partners Acquisition Corp.) ("NRXP" or the "Company") (NASDAQ: NRXP) who purchased stock prior to May 24, 2021 and still hold such stock. This investigation concerns the fairness of NRXP's 2021 de-SPAC merger.

NRXP SHAREHOLDER ALERT: Jakubowitz Law Notifies Shareholders of an Investigation into the Fairness of NRx Pharmaceuticals Inc.'s De-SPAC Merger

NEW YORK , May 24, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of NRx Pharmaceuticals Inc.  (f/k/a Big Rock Partners Acquisition Corp.) (NASDAQ: NRXP) The Gross Law Firm has commenced an investigation into the fairness of NRx Pharmaceuticals Inc.'s De-SPAC Merger. Shortly after the NRXP 2021 de-SPAC merger closed, NRXP stock began spiraling downwards.

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of an Investigation into the Fairness of NRx Pharmaceuticals Inc.'s De-SPAC Merger

NEW YORK , May 23, 2023 /PRNewswire/ -- The Klein Law Firm makes the following announcement to persons or entities who own NRx Pharmaceuticals Inc.  (f/k/a Big Rock Partners Acquisition Corp.) ("NRXP" or the "Company") (NASDAQ: NRXP) stock that was purchased prior to May 24, 2021: Our firm has commenced an investigation concerning fairness of NRXP's 2021 de-SPAC merger. Specifically, the NRXP de-SPAC merger investigation concerns whether this transaction unfairly harmed stockholders and whether all material facts were properly disclosed to stockholders.

NRXP ALERT: The Klein Law Firm Investigates the Fairness of NRx Pharmaceuticals Inc.'s De-SPAC Merger

NEW YORK , May 22, 2023 /PRNewswire/ -- Attention NRx Pharmaceuticals Inc. (f/k/a Big Rock Partners Acquisition Corp.) ("NRXP" or the "Company") (NASDAQ: NRXP) investors who purchased stock prior to May 24, 2021 and still hold such stock: An investigation has been commenced into the fairness of NRXP's 2021 de-SPAC merger. Shortly after the NRXP 2021 de-SPAC merger closed, NRXP stock began spiraling downwards.

MERGER INVESTIGATION ALERT: The Law Offices of Vincent Wong Notify Investors of an Investigation into the Fairness of NRx Pharmaceuticals Inc.'s De-SPAC Merger

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q1 2023 Earnings Call May 16, 2023 8:30 AM ET Company Participants Suzanne Messere - Investor Relations, Stern Stephen Willard - Chief Executive Officer and Director Seth Van Voorhees - Chief Financial Officer Jonathan C. Javitt - Chief Scientist and Director Conference Call Participants Edward Woo - Ascendiant Capital Markets LLC Jason Kolbert - Dawson James Securities Operator Good day, everyone, and welcome to NRx Pharmaceuticals' First Quarter 2023 Earnings Conference Call.

NRx Pharmaceuticals, Inc. (NRXP) Q1 2023 Earnings Call Transcript

Enrollment continues in the Phase 2b/3 clinical trial evaluating NRX-101 in Suicidal Treatment-Resistant Bipolar Depression; data expected in 4Q 2023 National educational campaign launched to further accelerate enrollment in Breakthrough Therapy Designation meeting for NRX-101 in Suicidal Treatment-Resistant Bipolar Depression with the U.S. FDA planned for 2Q 2023; on track to report topline clinical data in 4Q 2023 Ended quarter with $16.5 million in cash and cash equivalents Management to host a conference call and webcast today at 8:30 a.m. ET RADNOR, Pa.

NRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

RADNOR, Pa. , May 10, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it is rescheduling its first quarter quarterly investor conference call previously scheduled for Thursday, May 11, 2023 at 4:30pm ET to Tuesday, May 16, 2023 at 8:30am ET, due to scheduling conflicts.

NRx Pharmaceuticals Reschedules First Quarter 2023 Financial Results Conference Call

RADNOR, Pa. , April 27, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, a Delaware Corporation, today announced that it will release its first quarter 2023 financial results after the market closes on Thursday, May 11, 2023, via press release, which will be available on the Company's website at https://ir.nrxpharma.com/.

NRx Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q4 2022 Earnings Conference Call March 30, 2023 4:30 PM ET Company Participants Suzanne Messere - IR Stephen Willard - CEO Seth Van Voorhees - CFO Jonathan Javitt - Chief Scientist Conference Call Participants Jason Kolbert - Dawson James Vernon Bernadino - H.C. Wainwright Ed Woo - Ascendiant Capital Operator Good afternoon and welcome to the NRx Pharmaceuticals Full Year 2022 Results Conference Call.

NRx Pharmaceuticals, Inc. (NRXP) Q4 2022 Earnings Call Transcript

Over the past 12 months, the Company reinitiated its psychiatry development program post pandemic, transferred manufacturing of NRX-101 to the US, and initiated a clinical trial in suicidal treatment-resistant bipolar depression, which was recently reviewed by the independent Data Safety Monitoring Board (DSMB) The DSMB identified no safety or futility signals in the first 50 patients with Suicidal Treatment-Resistant Bipolar Depression enrolled in the trial; enrollment to continue as planned The current trial has been upgraded to a Phase 2b/3 study that may be used for a registrational filing; on track to report topline clinical data in 4Q 2023 Initiated registrational Phase 3 clinical trial of NRX-101 in patients with bipolar depression with acute suicidal ideation and behavior (ASIB) and held Type B meeting with U.S. FDA in 1Q 2023, which provided important input to the NRX-101 program Ended 2022 with $20.1 million in cash and cash equivalents and announced subsequent $2.9 million registered direct offering in March 2023 to support pipeline of life-saving therapeutics. Two international leaders in Psychiatry, Prof.

NRx Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Business Update

The independent Data Safety Monitoring Board recommended continuation of patient enrollment as planned.

NRx Pharmaceuticals Announces Positive Recommendation to Continue Enrollment in the Ongoing Trial of NRX-101 in Patients with Suicidal Treatment-Resistant Bipolar Depression

RADNOR, Pa. , March 17, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage CNS biopharmaceutical company, a Delaware Corporation, today announced that it will release its fourth quarter and full year 2022 financial results after the market closes on Thursday, March 30, 2023, via press release, which will be available on the Company's website at https://ir.nrxpharma.com/.

NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023

NRx Pharmaceuticals received approximately $2.9 million in cash from existing investors. Offering will assist the Company to initiate its National Treatment Protocol and Safety Database for NRX-101 for Treatment-Resistant Bipolar Depression with Risk of Self Harm.

NRx Pharmaceuticals Announces Close of $2.9 Million Registered Direct Offering

Company receives notice of the issuance of a U.S. patent covering the lead formulation, NRX-101, a glycine site NMDA antagonist in clinical trials to treat bipolar depression with acute and subacute suicidality; This new patent represents a third patent family, that now totals 48 issued patents worldwide with 42 additional pending patent applications. Patent covers the use of NRX-101 to treat patients suffering from depression, including bipolar depression or major depression (MDD) with or without suicidality and strengthens the Company's intellectual property position until at least 2033; Upon approval of NRX-101, this newly granted patent is expected to be "listable" in the U.S. Food and Drug Administration (FDA) Orange Book.

NRx Pharmaceuticals Builds on Its Intellectual Property Foundation for Neuropsychiatric Conditions - Adds New U.S. Patent to Portfolio

FDA discussed a broader indication of "treatment of recently acutely suicidal patients" with Bipolar Depression. This broader indication does not require ketamine as the only stabilization agent.

NRx Pharmaceuticals Reports Minutes of Recent U.S. Food and Drug Administration (FDA) Meeting on the Development of NRX-101 to Treat Severe Bipolar Depression in Patients with Suicidality

The Independent Data Safety Monitoring Board identified no safety concerns and issued a recommendation to continue trial enrollment. No treatment-related Serious Adverse Events with first 50 enrolled clinical trial participants RADNOR, Pa.

NRx Pharmaceuticals Reports Recommendations of Data Safety Monitoring Board for Trial of NRX-101 in Patients with Severe Bipolar Depression and Subacute Suicidal Ideation or Behavior

RADNOR, Pa. , Jan. 19, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage central nervous system (CNS) biopharmaceutical company, today announced that it had a meeting and a written response from the Food and Drug Administration (FDA) last week regarding its lead compound, NRX-101.

NRx Pharmaceuticals Provides Progress Update on Interactions with the FDA regarding Path to NDA Submission for NRX-101

RADNOR, Pa. , Jan. 5, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will be presenting a scientific update of its Phase 2 and Phase 3 development program for NRX-101 in the treatment of suicidal bipolar depression at the upcoming 6th Annual Neuroscience Innovation Forum by Sachs Associates ("6th Annual NIF").

NRx Pharmaceuticals to Present Scientific Update at the 6th Annual Sachs Associates Neuroscience Innovation Forum in Conjunction with the 2023 J.P. Morgan Healthcare Conference

First investigational drug for patients with Severe Bipolar Depression and Acute Suicidal Ideation/Behavior, a high unmet medical need Company received Breakthrough Therapy Designation and a Special Protocol Assessment ("SPA") for this trial helping to mitigate risks and accelerate the timing of this NRX-101 development program First trial site has been contracted with others expected in near future, first dosing of patients is expected in early 2023 Company to meet with research analysts and investors in conjunction with the upcoming JP Morgan Healthcare Conference RADNOR, Pa. , Jan. 3, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that its first clinical trial site has been contracted (with others expected in near future) and that first dosing of patients is expected in early 2023.

NRx Pharmaceuticals Initiates Phase 3 Trial Treating Patients with Bipolar Depression with Acute Suicidality - First Clinical Site Contracted

GENEVA, SWITZERLAND and RADNOR, PA / ACCESSWIRE / December 20, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), and NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals"), a clinical-stage central nervous system biopharmaceutical company, today announced the close of the definitive settlement agreements to resolve the pending litigation between Relief and NRx Pharmaceuticals' wholly owned subsidiary, NeuroRx, Inc (NeuroRx). Per the terms of the settlement, (i) NeuroRx has transferred to Relief all of the assets it used in the NRx aviptadil development program, including the regulatory filings, patent applications, clinical data, and the formulation of the aviptadil product it was previously developing, (ii) Relief now has the exclusive right and control going forward and the obligation to use commercially reasonable efforts to develop and commercialize an aviptadil product, (iii) Relief has agreed to use commercially reasonable efforts to continue the existing Right to Try Program for aviptadil in the U.S. for at least two years, (iv) Relief will pay NeuroRx milestone payments if it can successfully obtain commercial approval of an aviptadil product (whether for COVID-19 or any other indication), (v) Relief will pay NeuroRx royalties based on a percentage of future sales of an aviptadil product (whether for COVID-19 or any other indication), up to a maximum of $30 million in the aggregate, (vi) NRx and NeuroRx have agreed not to compete in the development of an aviptadil product in the future, and (vii) Relief and NeuroRx have dismissed their pending litigation.

Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements

Extensive global pharmaceutical leadership experience in clinical development, operations, and medical affairs Focused psychiatry practice expert in PTSD, Affective Disorders and Schizophrenia Proven track record in research as an investigator and academic grant-funded researcher Visiting Scholar  at Stanford University, Center for Precision Mental Health and Wellness Former roles at Boehringer Ingelheim and Pendulum Therapeutics RADNOR, Pa. , Dec. 5, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage central nervous system (CNS) biopharmaceutical company, today announced the appointment of Carrie M.

NRx Pharmaceuticals Announces the Appointment of Carrie M. Carretta, PhD, APN-BC, AHN-BC, PMHNP, Senior Vice President of Clinical Development and Medical Affairs

News for NRX Pharmaceuticals Stock (NRXP)